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CARM1 is a protein arginine methyltransferase (PRMT)
that acts as a coactivator in a number of transcriptional pro-
grams. CARM1 orchestrates this coactivator activity in part
by depositing the H3R17me2a histone mark in the vicinity of
gene promoters that it regulates. However, the gross levels of
H3R17me2a in CARM1 KO mice did not significantly decrease,
indicating that other PRMT(s) may compensate for this loss. We
thus performed a screen of type I PRMTs, which revealed that
PRMT6 can also deposit the H3R17me2a mark in vitro. CARM1
knockout mice are perinatally lethal and display a reduced fetal
size, whereas PRMT6 null mice are viable, which permits the
generation of double knockouts. Embryos that are null for both
CARM1 and PRMT6 are noticeably smaller than CARM1 null
embryos, providing in vivo evidence of redundancy. Mouse em-
bryonic fibroblasts (MEFs) from the double knockout embryos
display an absence of the H3R17me2a mark during mitosis and
increased signs of DNA damage. Moreover, using the combina-
tion of CARM1 and PRMT6 inhibitors suppresses the cell prolif-
eration of WT MEFs, suggesting a synergistic effect between
CARM1 and PRMT6 inhibitions. These studies provide direct
evidence that PRMT6 also deposits the H3R17me2a mark and
acts redundantly with CARM1.
Growing evidence shows that protein arginine methylation
plays a significant role in a number of cellular processes, includ-
ing gene regulation, mRNA splicing, translation, DNA damage
response, and signal transduction (1). In mammalian cells,
three types of methylarginine are catalyzed by nine protein ar-
ginine methyltransferases (PRMTs): Type I methyltransferases
generating asymmetric dimethylarginine (ADMA), Type II
methyltransferases generating symmetric dimethylarginine
(SDMA), and Type III methyltransferases generating monome-
thylarginine (MMA) (2). CARM1 (also called PRMT4) is recog-
nized as a transcriptional activator and belongs to the Type I
methyltransferase class. CARM1 deposits methylation marks
on both histone tails (3) and a number of nonhistone proteins
(4–6). CARM1 executes its coactivator function by modifying a
diverse substrate repertoire that often shares a splicing and/or
transcriptional theme (7–10) and includes the H3R17 histone
code mark as one of the major regulatory nodes (8, 11–13).
CARM1 can methylate histone H3 on both Arg-17 and Arg-26
residues but has a preference for Arg-17 over Arg-26 (14), at
least in vitro. It is the only mammalian PRMT known to meth-
ylate H3R17 (15); however, interestingly, ablation of CARM1 in
mouse embryonic fibroblasts (MEFs) does not result in the total
loss of the H3R17me2a mark (9), indicating that another
PRMT(s) maymethylate this site when CARM1 is absent.
PRMT6 is also a Type I arginine methyltransferase that cata-
lyzes the H3R2me2a mark, which in turn blocks enzymes from
depositing the adjacent H3K4me3 and impedes the binding of
the effectors of this transcriptional activation mark (16–18).
Thus, in this setting, PRMT6 functions as a transcriptional cor-
epressor. Most of the PRMTs methylate glycine- and arginine-
rich (GAR) motifs within their substrates, but CARM1 displays
unique substrate specificity and cannot methylate GAR motifs
(19, 20). Similar to other PRMTs, PRMT6 typically methylates
GAR motifs in substrates like HMGA1 and fibrillarin (21, 22),
but it also methylates non-GAR motifs in the HIV-1 Tat pro-
tein and on PRMT6 itself (an automethylation site) (23, 24).
PRMT6 methylates multiple sites on histones apart from
H3R2, including H2A/H4R3 (17), H2AR29 (25), and H3R42
(26), all of which are non-GAR motifs. Interestingly, both
CARM1 and PRMT6 can methylate histone H3 at Arg-42 (26),
suggesting that PRMT6 and CARM1 can share substrates in
some scenarios. Moreover, an in vitro methylation assay per-
formed on nearly 200 putative CARM1 substrates revealed that
PRMT6 could also methylate some of these substrates, but
PRMT1 and PRMT5 could not (27). Supporting this possible
redundant role for PRMT6 and CARM1 is the evidence that
both of these PRMTs function as coactivators in the context of
nuclear receptor–mediated transcriptional activation (28).
In this study, we performed in vitromethylation assays using
a panel of recombinant type I PRMTs, showing that PRMT6
can efficiently methylate the histone H3R17 site. The CARM1
knockout mice died at birth and showed a reduced fetal size (9).
In contrast, the PRMT6 knockout mice were viable (29), allow-
ing us to generate CARM1 knockout embryos on a PRMT6
knockout background.We found that embryos that are null for
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both CARM1 and PRMT6 are smaller than littermates that are
only null for CARM1. Importantly, MEFs generated from these
double knockout embryos displayed a reduction in the
H3R17me2a mark. We also detected elevated levels of DNA
damage in these double knockout cells. Using two recently
developed small molecular compounds that specifically inhibit
CARM1 (30) and PRMT6 (31), we show that there is a synergis-
tic effect between CARM1 and PRMT6 inhibition on cell prolif-
eration. Thus, these data unmask partially redundant functions
for CARM1 and PRMT6.
Results
PRMT6 generates the H3R17me2a mark in vitro
Previously, we showed that global levels of H3R17me2a are
not impacted by the loss of CARM1 (9), suggesting that other
PRMT(s) may also be able to methylate this site. To test this
hypothesis, we purified core histones from the aforementioned
CARM1 knockout MEFs and CARM1 enzyme-dead knock-in
MEFs (32) (Fig. S1A). Using two different H3R17me2a-specific
antibodies, we observed no decrease in H3R17me2a levels in
either the CARM1 knockout or the enzyme-dead knock-in MEF
lines (Fig. 1A). We confirmed the specificity of these antibodies
by using a panel of arginine-methylated peptides (Fig. S1B). The
Millipore antibody for H3R17me2a was used in the following
studies because there is an additional nonspecific band (Fig. 1A)
using the Abcam antibody. To search for the PRMTs that gener-
ate the H3R17me2a mark, we performed an in vitromethylation
assay with a few recombinant type I PRMTs: PRMT1, PRMT3,
PRMT6, and CARM1. All four PRMTs can methylate histone
H3, to varying degrees, to generate theH3R2me2amark; however,
only CARM1 and PRMT6 can generate the H3R17me2a mark
(Fig. 1B). Like CARM1, PRMT6 can generate the H3R26me2a
mark, albeit weakly (Fig. 1B). In addition, recombinant PRMT6
canmethylate a histoneH3 peptide (amino acids 10–27) that har-
bors the H3R17 motif; however, when the H3R17 site is masked
with a dimethyl mark or mutated to alanine, it can no longer be
methylated by PRMT6 (Fig. 1C and Fig. S1C). Finally, we per-
formed a time course in vitromethylation assay and observed
a steady increase in the methylation of both H3R17 and H3R2
sites by PRMT6 (Fig. 1D). These findings suggest that both
CARM1 and PRMT6 deposit an ADMA mark on H3R17, at
least in vitro.
PRMT6 overexpression results in elevated levels of the
H3R17me2a mark in HeLa cells
To determine whether PRMT6 canmethylate the H3R17 site
in mammalian cells, PRMT6 and CARM1 were overexpressed
in HeLa cells, and the levels of H3R17me2a were tested by
Western blotting. Increased levels of H3R2me2a by PRMT6
overexpression were observed as reported previously (18). In
addition, the levels of H3R17me2a were also elevated when
PRMT6 was ectopically expressed (Fig. 2A). In contrast, the
overexpression of CARM1 in HeLa cells did not cause an
increase in the H3R17me2a mark, likely because the ectopically
expressed CARM1 is predominantly cytoplasmic (Fig. S2A)
and does not engage its nuclear substrates. We also note that
the GFP-CARM1 protein level is lower than the endogenous
CARM1 levels (Fig. 2A), whereas ectopic PRMT6 expression is
much higher than its endogenous counterpart. When CARM1
is forced to express in the nucleus (using a GFP expression vec-
tor with a nuclear localization signal), a substantial increase in
the levels of H3R17me2a was observed as expected (Fig. S2, B
and C). Next, we analyzed a HeLa cell line that stably expresses
a TAP-tagged form of PRMT6. The protein G domains in the
TAP tag allow tight binding by IgG; thus, the ectopic expression
of PRMT6 can be visualized by any IgG-type antibody (33).
Again, increased H3R17me2a levels were observed in the
PRMT6-overexpressing lines (Fig. 2B). We also generated a cell
line that stably expresses an ER-PRMT6 fusion protein, which
was also linked to a FLAG tag (34). Upon treatment with ta-
moxifen, the fusion protein was stabilized and translocated into
the nucleus. In this experiment, we mixed ER-PRMT6 cells
with the same number of WT cells, to have PRMT6-overex-
pressing cells and control cells adjacent to each other in the
same field of view. This mixture culture was treated with ta-
moxifen and then prepared for immunofluorescence with
anti-FLAG and anti-H3R17me2a antibodies (Fig. 2C). FLAG-
tagged ER-PRMT6–positive cells showed significantly higher
H3R17me2a signals. Even though the H3R17me2a antibody
can recognize additional CARM1 substrates, the predomi-
nant signal generated by this antibody in ER-PRMT6–posi-
tive cells is due to an increase of the H3R17me2a histone
mark (Fig. S2D). Together, these findings indicate that
PRMT6 can methylate the H3R17 site both in vitro and in
cells.
Double knockout mice reveal cross-talk between CARM1 and
PRMT6
Because both CARM1 and PRMT6 have the ability to deposit
the H3R17me2a mark, it would be important to gauge the
degree of redundancy between these two PRMTs in mice. Pre-
viously, we made CARM1 knockout mice and showed that
CARM1 knockout embryos are similar in size to their WT lit-
termates at E12.5 but are significantly smaller than their litter-
mates at E18.5 (9). Whereas CARM1 knockout mice died at
birth, PRMT6 knockout mice survived to adulthood and did
not show any signs of stunted growth (29). Importantly,
no PRMT double knockouts have yet been performed. First,
we intercrossed PRMT61/2 CARM11/2 double heterozygous
mice to generate the single and double knockout embryos in
the same litter. At E13.5, both the CARM1 knockout and heter-
ozygous embryos were the same size, and the CARM1/PRMT6
double knockout embryos were distinctly smaller than the
CARM1 knockout embryos (Fig. 3A). At E18.5, CARM1 knock-
out embryos were smaller than CARM1 WT embryos, as we
previously reported (9), and the CARM1/PRMT6 double
knockout embryos were even smaller (Fig. 3B). Second, we
crossed CARM11/2 mice onto a PRMT6 null background,
which is fertile, and then intercrossed these mice. Again,
CARM1/PRMT6 double knockout embryos were smaller than
single knockout embryos at E13.5 (Fig. S3A). Genotyping was
performed by PCR (Fig. S3B), and Western blot analysis con-
firmed the loss of PRMT6 and CARM1 in both embryo extracts
and the corresponding cell lines derived from those embryos
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(Fig. S2C). Next, we used two independent sets of primaryMEF
lines derived fromWT, CARM12/2, PRMT62/2, and CARM1/
PRMT6 double knockout embryos and tested the level of
MMA, ADMA, and SDMA, using GAR motif antibodies, as
well as the H3R17me2a antibody (which recognizes a cadre of
CARM1 substrates (9)) (Fig. 3C). Interestingly, we observed
that the depletion of CARM1 and PRMT6 together led to the
disappearance of a strong ADMA signal of approximately 42
kDa (Fig. 3C), which could represent an as yet uncharacterized
shared substrate for these two PRMTs. In addition, the extracts
from CARM1/PRMT6 double knockout embryos display an
increase in both MMA and SDMA signals, suggesting that
PRMT5 may methylate these substrates when they are no lon-
ger blocked with ADMAmarks. The phenomenon of substrate
scavenging by PRMTs has previously been reported in both
PRMT1 knockout cells and CARM1 knockout cells (27, 35).
Figure 1. PRMT6 methylates histone H3 at the Arg-17 site in vitro. A, acid-extracted core histones from CARM1 WT, KO, and enzyme-dead KI MEFs were
immunoblotted using the indicated methyl-specific antibodies. Ponceau staining served as an additional loading control. B, in vitro methylation reactions
were performed using recombinant histone H3 (2 mg) with the indicated GST-tagged PRMTs (0.5 mg) in the presence of [3H]SAM. Reactions were separated on
SDS-PAGE, transferred to PVDF membranes for fluorograph, and immunoblotted using the indicated arginine methyl-specific antibodies to histone H3. C,
unmethylated histone H3 peptide and Arg-17–methylated peptides were incubated with GST-PRMT6 and [3H]SAM. Methylation signal by PRMT6 was
detected by fluorography.D, in vitromethylation reactions were performed using recombinant histone H3 with the indicated recombinant GST-fused PRMT in
the presence of [3H]SAMand incubated at the indicated time. Reactionswere separated on an SDS-polyacrylamide gel, transferred to PVDFmembranes for flu-
orograph, and immunoblotted using the indicated methyl-specific antibodies. *, nonspecific band detected by the Abcam H3R17me2a antibody. #, nonspe-
cific band detected by the H3R26me2a antibody.
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These data, particularly the reduced size of the CARM1/
PRMT6 double knockout embryos, provide genetic evidence
for a degree of redundancy between PRMT6 and CARM1. It
should be noted that a very small subset of CARM1 substrates
are likely methylated by PRMT6, because the H3R17me2a anti-
body, which cross-reacts with a large number of CARM1 sub-
strates, does not lose any immunoreactivity on whole-cell
lysates from PRMT6 knockout lines. We next focused on the
histone H3R17me2a mark itself, using acid-purified core histo-
nes from these mutantMEF lines.
Loss of CARM1 and PRMT6 leads to reduced H3R17me2a
levels in mitosis
Previous studies performed by Sakabe and Hart indicate that
the H3R17me2a mark is increased during mitosis (36). To vali-
date these published findings, we performed an expanded cell
cycle analysis of the H3R17me2a mark, along with known cell
cycle markers like cyclin B1 levels and histone H3S10 phospho-
rylation states (37). We synchronized HeLa cells with thymi-
dine and nocodazole and tested the levels of H3R17me2a and
H4R3me2a at the indicated time points after the cells were
released from cell cycle arrest. The intensity of the H3R17me2a
mark mirrors the H3Ser10ph signal, clearly supporting the reg-
ulation of this mark during the cell cycle (Fig. 4A). The
H4R3me2a mark was not altered during this time course (Fig.
4A). Next, we thus focused on studying the impact of CARM1
and PRMT6 loss on the H3R17me2a mark during mitosis,
when the level of this mark peaks.WT, CARM12/2, PRMT62/2,
and CARM1/PRMT6 double knockout MEFs were arrested in
mitosis, and the levels of H3R17me2a were tested by Western
blotting. Duringmitosis, H3R17me2a levels were elevated inWT,
CARM1 knockout, and PRMT6 knockout MEFs. However, ele-
vated levels of H3R17me2a were not seen in the double knockout
MEFs (Fig. 4B). Asynchronous CARM1/PRMT6 double knock-
out MEFs only showed a slightly lower level of H3R17me2a than
other asynchronous MEF cells, suggesting that other methyl-
transferases may help maintain the basal level of H3R17me2a in
the double knockout MEFs or that this antibody weakly recog-
nizes the unmethylated histone. H3Ser10ph is widely known to
be a biomarker during mitosis, and elevated levels of it are found
in the mitotic cells of all four genotypes tested (Fig. 4B). These
findings indicate that both CARM1 and PRMT6 are required for
the deposition of theH3R17me2amark duringmitosis.
CARM1/PRMT6 double knockout MEFs experience increased
double-strand DNA damage
CARM1 is reported to methylate p300, which promotes the
recruitment of BRCA1 to the promoter of p21 and is required
Figure 2. PRMT6 methylates histone H3 at Arg-17 site in cells. A, total cell lysates and core histones were extracted from HeLa cells transfected
with CARM1 alone and PRMT6 alone or together. The levels of CARM1, PRMT6, H3R17me2a, and H3R2me2a are detected by immunoblots using
methyl-specific antibodies. B, core histones were extracted from cell lines stably expressing NTAP or NTAP-tagged PRMT6. The levels of indicated
histone arginine methylation were detected by Western blotting. Ectopic expression of PRMT6 was monitored using an IgG-type antibody. C,
HEK293 cells stably expressing ER*-FLAG-PRMT6 were mixed with WT HEK293 cells with a 1:1 ratio in culture. The mixture was then treated with
4-hydroxytamoxifen for 48 h. The levels of FLAG-PRMT6 and H3R17me2a were visualized by immunostaining with the indicated antibodies. #, nonspe-
cific band.
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for the induction of p21 and GADD45 expression (38). Also,
p21 levels are up-regulated in PRMT6-deficient MEFs (29),
whereas GADD45a expression is suppressed by PRMT6 in the
early development of zebrafish (39). PRMT6 methylates DNA
polymerase b to promote efficient base excision repair (40).
CARM1 deposits marks that are read by the TDRD3 effector
protein, which in turn recruits TOP3B to resolve R-loops and
suppress DNA damage (41). These findings implicate both
CARM1 and PRMT6 in the DNA damage response. Thus, we
were interested to examine the impact of CARM1/PRMT6 loss
on the DNA damage response. PRMT6 knockout MEFs
showed increased staining for g-H2AX, as compared with WT
or CARM1 knockout MEFs, whereas the double knockout
MEFs showed the strongest signal of this biomarker for DNA
damage (Fig. 5A). Western blotting analysis further confirmed
that there is an increase in g-H2AX in double knockout MEFs
(Fig. 5B). In summary, we showed that there is significantly
increased DNA damage response in the CARM1/PRMT6 dou-
ble knockoutMEFs compared with the single knockout lines.
Synergistic effect between CARM1 and PRMT6 small molecule
inhibitions
Recent advances in small molecular compounds allow us to
specifically inhibit the enzyme activities of certain PRMTs (42).
TP-064 is a selective and noncompetitive inhibitor to CARM1
(30), and EPZ020411 is a potent and selective inhibitor to
PRMT6 (31). By using these compounds, we can avoid the vari-
ation between different cell lines. We thus hypothesize that the
loss of activity of both CARM1 and PRMT6 will result in
reduced cell proliferation, as suggested from the genetic experi-
ments (Fig. 3 (A and B) and Fig. S3A). To test this hypothesis,
we combined increasing concentrations of CARM1 (TP-064)
and PRMT6 (EPZ020411) inhibitors to treatWTMEFs, and we
tested the relative proliferation of the cells after 6 days (Fig.
6A). As individual agents, 3–10mM EPZ020411mildly inhibited
the cell growth of WT MEFs, whereas 3–10 mM of TP-064
slowed the proliferation rates. When combined, lower concen-
trations of TP-064 and EPZ020411 (0.3–3 mM) inhibited the
proliferation rates of WT MEF cells (Fig. 6A), suggesting that
Figure 3. CARM1/PRMT6double knockout embryos are smaller comparedwith single knockout. CARM1/PRMT6 double knockout embryos and their lit-
termates at age E13.5 (A) and E18.5 (B) were obtained from cross-breeding CARM11/2PRMT61/2 mice. C, primary MEFs were generated from the WT, CARM1
KO, PRMT6 KO, and DKO embryos. The gross levels of ADMA, MMA, SDMA, and CARM1 substrates (indicated by H3R17me2a antibody) are shown. *, high-
lighted ADMA signal only lost in CARM1/PRMT6 double knockout MEFs.
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there is a synergistic effect between the two compounds. After
4 days of the combined use of a 3 mM concentration of the
CARM1 inhibitor and 3mM PRMT6 inhibitor, a clear inhibition
of cell growth was observed with combination treatment over
single inhibitor treatment (Fig. S4). Next, we analyzed the com-
bined drug effect values shown in Fig. 6A by using the combina-
tion index theorem of Chou and Talalay (43), which is based on
the mass-action law principle. A combinatorial index (CI) of
,1 indicates synergism, whereas a CI of .1 demonstrates an-
tagonism. Effect-oriented mapping of the combination data
demonstrated synergism between the CARM1 inhibitor and
the PRMT6 inhibitor (Fig. 6B). These results show that the loss
of enzyme activity of both CARM1 and PRMT6 has dramatic
effects on cell proliferation rates and cell viability ofWTMEFs.
CARM1 and PRMT6 enzyme activities are required for normal
DNA damage response
Compared with the MEFs deficient in CARM1 or PRMT6
only, MEFs with both CARM1 and PRMT6 knocked out dis-
played increased g-H2AX levels (Fig. 5). To make sure this
effect on DNA damage response was not due to the idiosyncra-
sies related to the establishment of different primary MEF
lines, we applied the CARM1 inhibitor and the PRMT6 inhib-
itor to WT MEFs and tested the g-H2AX level by immuno-
staining (Fig. 6C) and Western blotting (Fig. 6D). The effect
of the CARM1 inhibitor was monitored by a pan-CARM1
substrate antibody (aCARM1sub) that we generated in-house
(Fig. 6D). The specificity of this antibody was demonstrated
by Western blotting with lysates from HEK293T cells treated
with different PRMT inhibitors, including the inhibitors
to type I PRMT (MS023), CARM1 (TP-064), and PRMT6
(EPZ020411). The signals generated by this antibody appreci-
ably decreased when CARM1 was inhibited (Fig. S5). With
the combination of CARM1/PRMT6 inhibitor treatment, a
decrease in H3R17me2a levels is observed (Fig. 6D), and a sig-
nificant signal increase in the DNA damage biomarker in WT
MEFs was seen in both assays (Fig. 6, C and D). These data
further suggest that CARM1 and PRMT6 work together to
ensure and maintain DNA integrity and that the enzyme
activities of both are required for this regulation to occur.
Discussion
In this study, we discovered that PRMT6, like CARM1, has
the ability to methylate histone H3 at Arg-17 both in vitro and
in vivo (Figs. 1 and 2). To date, PRMT6 has been shown to de-
posit methylation marks on histone H3R2 (16), H3R17, H3R42
(26), H2A/H4R3 (17), and H2AR29 (25). Among these sites,
H3R2me2a and H2AR29me2a are associated with repressed
gene expression (16, 17, 25), whereas H3R17me2a, H4R3me2a,
and H3R42me2a are generally associated with transcriptional
activation (26, 44). Histone H3R2 was thought to be the major
histone target site of PRMT6 in cells, and PRMT6 was widely
considered a transcriptional repressor (29, 44–46); however, in
a few other cases, PRMT6 was reported to act as a transcrip-
tional coactivator (34, 47). Moreover, recent RNA-Seq data
from PRMT6 knockout cells showed almost equal amounts of
up-regulated and down-regulated genes (48). Interestingly,
;25% of deregulated genes have promoters that are associated
with H3R2me2a peaks, and 70% of these H3R2me2a-marked
genes are down-regulated in the absence of PRMT6 (48). These
data suggest that PRMT6 functions as both a transcriptional
repressor and activator, depending on the context. It is unclear
how these opposite functions of PRMT6 are regulated, but it
could be due to its presence in different transcriptional com-
plexes, which may direct the enzyme activity of this PRMT to
different sites on histone tails. Our data revealed that PRMT6
can methylate H3R17 and that it can impinge on the CARM1
pathway.
Most PRMTs, including PRMT6, prefer a GARmotif in their
substrates, whereas CARM1 has a preference for a proline resi-
due near themethylated arginine (4, 19). In a few cases, PRMT6
was shown to methylate non-GAR motifs in HIV Tat proteins
and in PRMT6 itself (23, 24). Another study showed that both
CARM1 and PRMT6 can methylate histone H3 at Arg-42,
stimulating the activation of p53-dependent transcription in
vitro (26). In this study, we showed that both CARM1 and
PRMT6 can methylate H3R2, H3R17, and H3R26 in vitro (Fig.
1, B and D), with varying degrees of efficiency. In cells, we
Figure 4. CARM1 and PRMT6 are both required for the elevation of
H3R17me2a in mitosis. A, HeLa cells were arrested in mitosis by treatment
with thymidine followed by nocodazole, and the cells were harvested after
the cells were released from cell cycle arrest at the indicated time points.
Then total cell lysates and core histones were prepared and probed with the
indicated antibodies. Core histones and total cell lysates from asynchronized
(Asyn) HeLa cells were loaded as controls. B, core histones from asynchronous
(A) and mitotic (M) WT, CARM1 KO, PRMT6 KO, and DKO primary MEFs were
immunoblotted using the indicated antibodies.
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validated that PRMT6 has the ability to methylate H3R17 (Fig.
2), and we showed the loss of an unknown methylated protein
in CARM1 and PRMT6 double knockout MEFs (Fig. 3). Our
data further support the hypothesis that CARM1 and PRMT6
share additional common substrates (Fig. 3C), apart from
H3R17 andH3R42.
The best example of PRMTs collaborating during certain cel-
lular processes is PRMT1 and PRMT5. Together, they regulate
hypoxia and ischemia-induced apoptosis (49), the formation of
stress granules (50), cell proliferation (51), and RNA splicing
(52). Besides the collaboration between PRMT1 and PRMT5,
PRMT1 and CARM1 work together to synergistically regulate
p53-dependent and p53-independent genes (53–56). Also,
knocking down PRMT1 or CARM1 leads to an increased RNA-
binding ability of hnRNPUL1 (57). Even though PRMT6 and
PRMT1 in vitro share similar substrates, such as H4R3 (58),
Npl3 (21), and TOP3B (59), not much is known about their col-
laboration in vivo. In the case of CARM1 and PRMT6, they are
known to work together to positively regulate hormone-de-
pendent transcription (28, 60). Knockdown of both CARM1
and PRMT6 significantly inhibits the estrogen-stimulated pro-
liferation of breast cancer cells, but it does not inhibit cell pro-
liferation in the absence of estrogen (28). In a recent study,
MCF-7 cells were treated with a small molecular inhibitor of
both CARM1 and PRMT6, and the estrogen-dependent tran-
scription of GREB1 significantly increased, whereas the loss of
CARM1 alone only partially mimicked this effect (61). Finally,
in early mouse embryonic development, CARM1 methylation
of the H3R26 site seems to be critical for driving cell fate deci-
sions (62, 63), but it remains unclear whether PRMT6, which
can weakly methylate the H3R26 site (Fig. 1, B and D), func-
tions redundantly in this setting. In summary, previous reports
showed that the combinatorial effect of CARM1 and PRMT6
regulates cell proliferation in a hormone-dependent manner
(28). Here, we provide a mechanistic explanation for the
reported synergy between CARM1 and PRMT6, which relies
on the ability of these two PRMTs tomethylate the samemotifs
on histone tails and perhaps also on nonhistone substrates.
Materials and methods
Antibodies
Two H3R17me2a antibodies used in this study were from
Millipore (#07-214) and Abcam (#ab8284), mostly from Milli-
pore (if not indicated). Other antibodies were anti-H3R2me1
(Abcam, #ab15584), anti-H3R2me2a (Millipore, #07-585), anti-
H3R26me2a (Millipore, #07-215), anti-H4R3me2a (Active
Motif, #39705), anti-histone H3 (Abcam, #ab18521), anti-
FLAG (Sigma, #F1804), anti-b-actin (Sigma, #A1978), anti-
CARM1 (Bethyl, #A300-421A), anti-PRMT6 (Bethyl, #A300-
929A), anti-H3Ser10ph (Active Motif, #61623), anti-cyclin B1
(BD Biosciences, #554177), anti-H3K9me3 (Active Motif,
Figure 5. Increased DNA damage in CARM1/PRMT6 double knockout primary MEFs. A, two individual MEF lines generated fromWT, CARM1 KO, PRMT6
KO, and DKO embryos were immunostained with anti-g-H2AX antibody. In a certain field of view, cells with more than five g-H2AX foci were counted. Also,
the average number of g-H2AX foci per nucleus was calculated and plotted. B, acid-extracted core histones as well as total cellular lysates from WT, CARM1
KO, PRMT6 KO, and DKOMEFs were separated on an SDS-polyacrylamide gel and subsequently immunoblotted with the indicated antibodies.
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#39161), anti-SDMA (collaboration with Cell Signaling Tech-
nologies), anti-ADMA (collaboration with Cell Signaling Tech-
nologies), anti-MMA (collaboration with Cell Signaling Techno-
logies), pan-CARM1 substrate antibody (made in-house),
anti-g-H2AX (Millipore, #05-636), and anti-histone H2A
(Millipore, #ABE327).
Knockout mice and genotyping
CARM11/2mice (9) were bred with PRMT62/2mice (29) to
generate CARM11/2 PRMT61/2 double heterozygous mice.
CARM11/2 PRMT61/2 mice were further intercrossed to pro-
duceWT, CARM12/2, PRMT62/2, and CARM12/2PRMT62/2
embryos. For timed pregnancies, CARM11/2PRMT61/2 mice
were mated overnight. Females were inspected for vaginal plugs
the following morning, and the following noon was taken as day
0.5 of gestation (E0.5). Genomic DNA was isolated from liver
biopsies and analyzed by PCR using the following primers: 59-
AGT CCA TGC TGA GCT CCG T-39 and 59-TCC ATG CAG
CTC ATA TCC A-39 for PRMT6WT allele; 59-AAG GTC ACT
GGA AGA AGG-39 and 59-ACT CTC AGA ATT GCC TAG-39
for PRMT6 knockout allele; 59-CCC ACT TCT GTT ACC TCC
TTT G-39 and 59-TAA CTA AAA GAA AAT GGA ATG G-39
for CARM1 genotyping (both WT allele and KO allele). All
mouse experiments were reviewed and approved by an institu-
tional animal care and use committee at MD Anderson Cancer
Center.
Plasmids and cell culture
GST-tagged PRMTs were expressed from constructs based
on the vector pGEX-6P-1 (Amersham Biosciences). Constructs
expressing GST-PRMT1, GST-PRMT3, GST-CARM1, and
GST-PRMT6 have been described previously (21). NTAP-
PRMT6 was generated by cloning PRMT6 cDNA into pCeMM
NTAP(GS) vector (EUROSCARF). CARM1 and PRMT6
cDNAs were inserted into peGFP-C1 vector to generate
constructs expressing GFP-tagged CARM1 and PRMT6
in mammalian cells. GFP-NLS-CARM1 was generated by
inserting mouse CARM1 coding sequence into the BglII site
Figure 6. Synergistic effect of CARM1 and PRMT6 inhibitors on the cell proliferation of WT MEFs. A, WT MEFs were treated with a combination of the
indicated concentration of CARM1 inhibitor (CARM1i) and PRMT6 inhibitor (PRMT6i) for a total of 6 days. At the end of the culture, cell counting was performed
with the CellTiterGlo® kit, and the viabilities of different drug treatment groups were normalized by the group with no CARM1 inhibitor or PRMT6 inhibitor
(which was set as 100%). B, normalized cell viabilities lower than 100% in Awere allowed to be used to calculate the CI values, with CompuSyn software (Com-
boSyn, Inc., Paramus, NJ, USA). Synergistic interactions are implied by values of,1, whereas values of.1 indicate antagonistic interactions. C and D, WTMEFs
were treated with 3 mM CARM1 inhibitor alone, 3 mM PRMT6 inhibitor alone, or the inhibitors combined for 6 days. The treated cells were stained with anti-
g-H2AX or DAPI to visualize the DNA damage foci in the nucleus (C) or lysed forWestern blotting to detect the levels of g-H2AX and H3R17me2a (D).
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in pAcGFP1-Nuc (Takara). CARM1 WT, KO, and KI MEFs
have been described previously (32). HeLa and HEK293 cell
lines were obtained from ATCC. HeLa cells stably express-
ing NTAP or NTAP-PRMT6 were generated by transfecting
NTAP orNTAP-PRMT6 construct intoWTHeLa cells, followed
by selection of single clones using G418. Stable ER*-FLAG-
PRMT6 HEK293 cell line has been described previously (34).
Individual embryos (WT, CARM1 KO, PRMT6 KO, CARM1,
and PRMT6 double KO (DKO)) from CARM11/2PRMT61/2
inbred at E13.5 were sheared and placed into culture to generate
primaryMEF cells as described previously (32). All cell lines were
maintained in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum.
Histone purifications
Core histones were purified from cell pellets using a Histone
Purification Mini kit (Active Motif) according to the manufac-
turer’s instructions.
In vitro methylation
GST-tagged PRMT1, PRMT3, CARM1, and PRMT6 were
purified and used as an enzyme source. Recombinant histones
or peptides were incubated with GST-tagged PRMTs and [3H]
SAM at 30 °C for 1 h (or the indicated time course). SDS load-
ing buffer was added to the reactions, and the samples were
boiled for 5 min. Samples were then applied to electrophoresis
on an SDS-polyacrylamide gel and transferred to a PVDFmem-
brane. Then the membrane was dried, and the radioactive sig-
nals were recorded with X-ray films.
Immunostaining
Cells were seeded on coverslips. At the end of cell culture,
the indicated cells were rinsed with PBS and subsequently fixed
and permeabilized in buffer containing 2% paraformaldehyde
and 0.5% Triton X-100 in PBS at 4 °C for 30 min. Then the cells
were blocked in 20% fetal bovine serum and incubated with the
indicated primary antibody for 1 h at room temperature. Cells
were then washed and incubated with Alexa Fluor 647–conju-
gated secondary antibody (Invitrogen) for 30 min. Finally, they
were washed again and stained with DAPI for 5 min at room
temperature.
Western blotting
Cells were harvested and lysed, and the cell lysates were
applied to Western blot analysis. In brief, cells were harvested
and washed three times with cold PBS, and then radioimmune
precipitation assay buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1% Nonidet P-40, 0.1% SDS, 1% sodium deoxycholate, 5
mM EDTA, supplemented with proteinase inhibitor mixture)
was added to obtain the cell lysates. Cell debris was pelleted
and discarded, whereas the supernatant was kept. Protein sam-
ples were added with SDS loading buffer and boiled for 5 min,
followed by SDS-PAGE. Then the proteins were transferred to
a PVDF membrane. The membrane was blocked with 5% fat-
free milk for 1 h at room temperature and then incubated with
primary antibodies at 4 °C overnight. The blot was then washed
three times with PBST and incubated with secondary antibod-
ies for 1 h at room temperature. After washing three times with
PBST, the membrane was incubated with ECL reagent, and the
signals were detected on X-ray film.
Synchronization
HeLa cells were cultured to 40% confluence and treated with
2 mM thymidine for 24 h. Then thymidine was removed by
washing with PBS. Fresh medium was then added, and the cells
were incubated for 3 h. Afterward, nocodazole was added at a
concentration of 100 ng/ml for 12 h to arrest cells at mitosis.
PRMT inhibitor treatment and cell counting
TP-064 (Cayman Chemical, #20256) and EPZ020411 (Cay-
man Chemical, #19160) were dissolved in DMSO. Mouse em-
bryonic fibroblasts were treated with these drugs for a total of 6
days, with the medium and drugs changed every other day. At
the end of the culture, CellTiter-Glo luminescent kit (Promega)
was used to measure the cell viability. Briefly, cells were trypsi-
nized and diluted with fresh Dulbecco’s modified Eagle’s me-
dium to the culture volume. Then 100 ml of prewarmed reagent
was directly added to 100 ml of the harvested cell culture. The
plates were shaken on a horizontal shaker at room temperature
for 10 min and applied to a luminescence plate reader. Cell via-
bilities were normalized to the untreated group.
Data availability
The data sets supporting the conclusions of this article are
included within the article and the supporting information.
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